Phase 2 biotech developing a selective FASN inhibitor for NASH and cancers.
Industry: Health Care
Latest Trade: $5.61 +0.19 (+3.5%)
First Day Return: -0.3%
Return from IPO: -66.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 06/23/2023 |
Offer Price | $16.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 5.3 |
Deal Size ($mm) | $85 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 07/13/2023 |
Offer Price | $16.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 5.3 |
Deal Size ($mm) | $85 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Goldman Sachs |
TD Cowen |
more |
Company Data | |
---|---|
Headquarters | San Mateo, CA, United States |
Founded | 2006 |
Employees at IPO | 10 |
Website www.sagimet.com |